JEQP:XETRA:XETRA-

| Others |

Last Closing

USD 25.175

Change

+0.04 (+0.16)%

Market Cap

N/A

Volume

0.03M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-18 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
USUP:XETRA UBS(Lux)Fund Solutions – MSC..

N/A

USD 1.07B
WEBH:XETRA Amundi MSCI USA UCITS ETF Acc ..

+0.24 (+0.62%)

USD 0.86B
CA1:XETRA Circus SE

-0.20 (-0.98%)

USD 0.51B
7V0:XETRA Darwin AG

+1.20 (+4.41%)

USD 0.08B
8PSB:XETRA Invesco Physical Markets PLC O

-0.03 (-0.10%)

N/A
ABCH:XETRA 21Shares Bitcoin Cash ETP

+0.59 (+4.74%)

N/A
TY3S:XETRA WisdomTree US Treasuries 10Y 3..

N/A

N/A
AXTZ:XETRA 21Shares Tezos staking ETP

+0.21 (+4.52%)

N/A
42FB:XETRA AI/ML Innovations Inc.

+0.01 (+21.95%)

N/A
BTIC:XETRA Invesco Physical Bitcoin ETN E..

+1.76 (+1.99%)

N/A

ETFs Containing JEQP:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 1.51% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.51% N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike